MarketLens
Sign Up

Fennec Pharmaceuticals: Is PEDMARK's Q1 2026 Performance a Game Changer

4 months ago
SHARE THIS ON:

Fennec Pharmaceuticals: Is PEDMARK's Q1 2026 Performance a Game Changer

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

Pharming Group's RUCONEST revenue showed a sequential sales rebound, but oral competition could challenge stabilization. The bull case assumes manageable issues, potentially buying time for Joenja to ...
Stock News•3 weeks ago

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

MannKind highlighted early demand for FUROSCIX ReadyFlow and momentum in the pediatric Afrezza launch, with three 2026 catalysts: pediatric approval, ReadyFlow launch, and Phase 1b MNKD-201 data in IP...
Stock News•3 weeks ago

Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026

Fennec Pharmaceuticals reported that Pedmark cut ASHA-defined hearing loss to 24.0% of patients in a Japanese Phase 2 study, versus a 56.4% historical benchmark (P=0.001). The primary endpoint was met...

Breaking News

View All →

No topics available at the moment

Top Headlines

View More →
Stock News•54 minutes ago

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alphabet Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GOOGL, GOOG

Stock News•1 hour ago

Why the Market Dipped But Meta Platforms (META) Gained Today

Stock News•1 hour ago

Nvidia in 5 Years: Where the Stock Could Be Headed

Stock News•2 hours ago

UK finance minister Healey to target online marketplaces in tax crackdown, The Times reports

Stock News•2 hours ago

Character.AI owes Google and Big Law firms nearly $7M, court filings show